黏膜愈合在炎症性肠病中的临床应用

摘要

Until the late-1990s, symptomatic remission has been the key parameter for efficacy evaluation of inflammatory bowel disease (IBD).In recent years, mucosal healing (MH) has been included into efficacy evaluation of IBD, and has been used as an important endpoint and treatment goal in clinical trails.MH may change the natural course of IBD, so as to achieve sustaining clinical remission, reduction of hospitalization rate and surgical risk of IBD patients.This article reviewed the clinical application of MH in IBD.%至上世纪90年代末,症状缓解仍是炎症性肠病(IBD)疗效评估的重要指标.近年,黏膜愈合(MH)逐渐被纳入IBD的疗效评估,并作为临床试验的重要终点和治疗目标.MH可改变IBD的自然病程,以达持续临床缓解,由此降低患者的住院率和手术风险.本文就MH在IBD临床应用中的价值作一综述.